Treat DVT with low molecular weight heparin.

Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalizationto receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight hepa...

Descripción completa

Detalles Bibliográficos
Publicado en:Nurse Practitioner Vol. 28; no. 10; pp. 22 - 28
Autores principales: Nadeau C, Varrone J
Formato: care plan CEU exam questions Journal Article
Publicado: Lippincott Williams & Wilkins Oct2003
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106699306&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106699306
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        03611817
        39E
      jtl: Nurse Practitioner
      issn: 03611817
      maglogo: N
    pubinfo:
      dt: Oct2003
      vid: 28
      iid: 10
      pid: 5086
      pub: Lippincott Williams & Wilkins
      place: Baltimore, Maryland
    artinfo:
      ui:
        106699306
        106699306
        2004030748
        10.1097/00006205-200310000-00010
        NLM14560128
        106699306
      ppf: 22
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Treat DVT with low molecular weight heparin.
      aug:
        au:
          Nadeau C
          Varrone J
        affil: Family Nurse Practitioner, Certified Anticoagulation Care Provider, NYU Hospitals Center Anticoagulation Management Service
      sug:
        subj:
          Heparin, Low-Molecular-Weight Therapeutic Use
          Pulmonary Embolism Drug Therapy
          Venous Thrombosis Drug Therapy
          Ambulatory Care
          Education, Continuing (Credit)
          Heparin, Low-Molecular-Weight Contraindications
          Heparin, Low-Molecular-Weight Economics
          Heparin, Low-Molecular-Weight Pharmacokinetics
          Nurse Practitioners Education
          Patient Education
          Pulmonary Embolism Prevention and Control
          Venous Thrombosis Prevention and Control
      ab: Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalizationto receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.
      pubtype: Academic Journal
      doctype:
        care plan
        CEU
        exam questions
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N